

Almirall and Forest Laboratories announce commercial availability of Tudorza™ Pressair™ in U.S. pharmacies

- **New treatment for COPD now available in U.S. pharmacies**
- **In Europe, acclidinium is already available in Germany, the UK and Denmark**
- **Acclidinium + formoterol phase III topline results available in first half 2013**

Barcelona and New York, December 11th, 2012 - Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (NYSE:FRX) announced today that Tudorza™ Pressair™ (acclidinium) is now available in pharmacies throughout the United States. Tudorza™ is a long-acting anticholinergic recently approved by the U.S. Food and Drug Administration (FDA) for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Tudorza™ is the first long-acting inhaled anticholinergic approved by the FDA for COPD in over 8 years and is administered twice daily through the preloaded, multidose Pressair™ inhaler.

Almirall granted commercialization rights in the U.S. for acclidinium to Forest Laboratories, Inc. Forest and Almirall will co-promote acclidinium in Canada.

Marketing rights for acclidinium were also granted to Kyorin Pharmaceutical Co., Ltd in Japan and Daewoong Pharmaceutical Co. Ltd. in Korea. Additionally, Almirall has recently given rights of joint commercialization in the majority of European member states and a number of non-EU countries to Menarini, and new agreements have been added for Australia and New Zealand through Invida, a company belonging to the Menarini group. Almirall maintains rights for the rest of the world.

In Europe, acclidinium has been launched by Almirall in Germany, the UK and Denmark, under the brand name Eklira® Genuair®.

The phase III combo of acclidinium plus formoterol for COPD is on track and patients' recruitment is progressing. Topline results are expected in the first half of 2013.

Media information:

Ketchum

Bianca Daneshfar-Nia
bianca.daneshfar-nia@ketchumpleon.com
Tel.: +44 20 76113510

Investor Relations enquiries:

Almirall

Jordi Molina
jordi.molina@almirall.com
Tel.: +34 93 291 30 87

Contact Forest:

Forest Laboratories, Inc.
Frank J. Murdolo, +1-212-224-6714
Vice President - Investor Relations
media.relations@frx.com

About Tudorza™ Pressair™

Tudorza™ Pressair™ (aclidinium bromide inhalation powder 400mcg) is an anticholinergic for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. When given by inhalation, Tudorza™ produces bronchodilation by inhibiting the muscarinic M3 receptor in the airway smooth muscle.

Tudorza™ provides statistically significant improvements in bronchodilation, as measured by change from baseline in morning pre-dose trough FEV₁ at 12 weeks (the primary endpoint) and 24 weeks compared to placebo. Mean peak improvements in lung function (FEV₁) assessed after the first dose of Tudorza™ were similar to those observed at week 12. Tudorza is not indicated for the initial treatment of acute episodes of bronchospasm (ie, rescue therapy).

Tudorza™ is administered using a multiple-dose dry powder inhaler, Pressair™, which delivers 60 doses of aclidinium bromide powder for inhalation. The Pressair™ inhaler has a colored control window which confirms successful inhalation of the full dose, and a dose indicator to let patients know how many doses remain in the inhaler. For a complete description of how to use the Tudorza™ Pressair™ inhaler, see the step-by-step Instructions for Use within the Prescribing Information.

About COPD

COPD, or chronic obstructive pulmonary disease, is a common, progressive, and debilitating lung disease characterized by persistent airflow limitation that makes it hard to breathe. The World Health Organization (WHO) has described COPD as a global epidemic; an estimated 64 million people have COPD worldwide. More than 3 million people died of the condition in 2005, which is equal to 5% of all deaths globally that year. Total deaths from COPD are projected to increase by more than 30% in the next 10 years without interventions to cut risks, particularly exposure to tobacco smoke. WHO predicts that COPD will become the third leading cause of death worldwide by 2030. COPD is already the third leading cause of death in the U.S.

In patients with COPD the airways in the lungs typically lose their elasticity, produce excess mucus and become thick and inflamed, limiting the passage of air. The most common symptoms of COPD are breathlessness (or a "need for air"), abnormal sputum (a mix of saliva and mucus in the airway), and chronic cough. Daily activities, such as walking up a short flight of stairs or carrying a suitcase, can become very difficult as the condition gradually worsens. New therapies to treat this debilitating disease may be of value.

Important Safety Information

Tudorza™ Pressair™ is not indicated for the initial treatment of acute episodes of bronchospasm (ie, rescue therapy).

Inhaled medicines, including Tudorza™, may cause paradoxical bronchospasm. In addition, immediate hypersensitivity reactions may occur after administration of Tudorza™. If either of these occurs, treatment with Tudorza™ should be stopped and other treatments considered.

Tudorza™ should be used with caution in patients with narrow-angle glaucoma or urinary retention. Instruct patients to consult a physician immediately should any signs or symptoms of narrow-angle glaucoma or prostatic hyperplasia or bladder-neck obstruction develop.

Patients with a history of hypersensitivity reactions to atropine should be closely monitored for similar hypersensitivity reactions to Tudorza™. Use with caution in patients with severe hypersensitivity to milk proteins.

The most common adverse reactions ($\geq 3\%$ incidence and greater than placebo) were headache (6.6% vs 5.0%), nasopharyngitis (5.5% vs 3.9%), and cough (3.0% vs 2.2%), for Tudorza and placebo, respectively.

About Almirall

Almirall is a pharmaceutical company committed to innovate through valuable medicines. Headquartered in Barcelona, Spain, it researches, develops, manufactures and commercialises its own R&D and licensed drugs with the aim of improving people's health and wellbeing now and to future generations. Almirall medicines, focused on respiratory, dermatology, gastrointestinal and pain, are currently in over 70 countries while the company has direct presence in Europe, Mexico and Canada through 13 affiliates.

For further information please visit: www.almirall.com.

About Forest Laboratories

Forest Laboratories' (NYSE: FRX) longstanding global partnerships and track record developing and marketing pharmaceutical products in the United States have yielded its well-established central nervous system and cardiovascular franchises and innovations in anti-infective, respiratory, gastrointestinal and pain management medicine. Forest's pipeline, the most robust in its history, includes product candidates in all stages of development across a wide range of therapeutic areas. The Company is headquartered in New York, NY. To learn more, visit www.FRX.com.

Except for the historical information contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in Forest Laboratories' Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any subsequent SEC filings. Forest assumes no obligation to update forward-looking statements contained in this release to reflect new information or future events or developments.